Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
| ▸ | FURIN | P09958 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18122900 | 0.94 | SIRT5 (0.36) | SIRT5FURIN | |
| SCHEMBL19170464 | 0.92 | SIRT5 (0.31) | SIRT5FURIN | |
| SCHEMBL21322625 | 0.90 | C3AR1 (0.32) | — | |
| SCHEMBL19170915 | 0.83 | FURIN (0.35) | FURIN | |
| SCHEMBL19203574 | 0.83 | MEN1 (0.31) | — | |
| SCHEMBL24722180 | 0.79 | SIRT2 (0.30) | FURIN | |
| SCHEMBL19203552 | 0.78 | SIRT5 (0.40) | SIRT5FURIN | |
| SCHEMBL19170914 | 0.76 | FURIN (0.35) | SIRT5FURIN | |
| SCHEMBL18122899 | 0.76 | — | — | |
| SCHEMBL24860389 | 0.76 | SIRT5 (0.37) | SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463749-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10463749-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | HNMT, SLC10A1, SLC10A2 | SIRT5 2864/4885FURIN 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.